Supplementary Materials and Methods; Supplementary Tables 1-3; Supplementary Figures 1-2 from BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table 1. Emergence of BRAF mutations in cfDNA; Supplementary Table 2. Patients with BRAF V600K mutations in FFPE tumor and plasma cfDNA samples; Supplementary Table 3. Experimental therapies in 34 patients with longitudinal collection of plasma cfDNA; Supplementary Figure 1. A. Among the 160 patients whose cfDNA samples were tested for BRAF mutations, the median overall survival duration of the 113 patients with a BRAF-mutant cfDNA percentage of 0% (10.0 months, 95% confidence interval [CI], 7.2-12.8 months; blue) was longer than that of the 47 patients with a BRAF-mutant cfDNA percentage of >0% (7.0 months, 95% CI, 2.5-11.5 months; red), but this difference was not significant (P=0.09). B. Among these same 160 patients, the median overall survival duration of the 126 patients with a BRAF-mutant cfDNA percentage of <1% (10.5 months, 95% CI, 8.4-12.6 months; blue) was significantly longer than that of the 34 patients with a BRAF-mutant cfDNA percentage of greater than or equal to 1%(5.5 months, 95% CI, 3.4-7.6 months; red; P=0.006). C. Among the 47 patients with cfDNA BRAF mutations, the median overall survival duration of the 21 patients with a BRAF-mutant cfDNA percentage of less than or equal to 2% (11.2 months, 95% CI, 10.4-12.0 months; blue) was longer than that of the 26 patients with a BRAF-mutant cfDNA percentage of >2% (4.4 months, 95% CI, 3.2-5.6 months; red), but this difference was not statistically significant (P=0.05). D. Among the 62 patients whose formalin-fixed paraffin-embedded tumor samples had BRAF mutations, the median overall survival duration of the 37 patients with a BRAF-mutant cfDNA percentage of less than or equal to 2% (14.6 months, 95% CI, 9.4-19.8 months; blue) was significantly longer than that of 25 patients with a BRAF-mutant cfDNA percentage of >2% (4.5 months, 95% CI, 3.0-6.0 months; P=0.001). Supplementary Figure 2. A. The median amount of cfDNA in plasma of the 160 patients whose cfDNA was tested for BRAF mutations was 60 ng/ml. The median overall survival duration of the 81 patients with a cfDNA amount in plasma less than or equal to 60 ng/ml (8.9 months, 95% confidence interval [CI], 4.8-13.0 months; blue)was similar to that of the 79 patients with a cfDNA amount in plasma >60 ng/ml (8.7 months, 95% CI, 5.2-12.2 months; red; P=0.91). B. The median cfDNA concentration of these same 160 patients was 4.6 ng/μl. The median overall survival duration of the 82 patients with a cfDNA concentration <5 ng/IJI (9.5 months, 95% Cl, 5.8-13.2 months; blue) was similar to that of the 78 patients with cfDNA concentrations 5 ng/ml (8.7 months, 95% Cl, 5.4-12.0 months; red), but this difference was not significant (P=0.89).
Authors: Filip Janku, Helen J. Huang, Bart Claes, Gerald S. Falchook, Siqing Fu, David Hong, Nishma M. Ramzanali, Giovanni Nitti, Goran Cabrilo, Apostolia M. Tsimberidou, Aung Naing, Sarina A. Piha-Paul, Jennifer J. Wheler, Daniel D. Karp, Veronica R. Holley, Ralph G. Zinner, Vivek Subbiah, Rajyalakshmi Luthra, Scott Kopetz, Michael J. Overman, Bryan K. Kee, Sapna Patel, Benoit Devogelaere, Erwin Sablon, Geert Maertens, Gordon B. Mills, Razelle Kurzrock, Funda Meric-Bernstam
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362495035